HCA Healthcare Gets Price Target Bumps By Analysts After Upbeat Q1 Results

HCA Healthcare HCA reported better-than-expected Q1 results and revised FY23 guidance.

HCA Healthcare reported Q1 FY23 revenues of $15.59 billion, compared to $14.94 billion a year ago, missing the consensus of $15.27 billion. EPS of $4.93 was higher than the $4.12 reported a year ago, surpassing the estimate of $3.93.

For FY23, HCA Healthcare raised revenues guidance to $62.5-$64.5 billion from $61.5-63.5 billion compared to the consensus Of $62.61 billion.

HCA Healthcare shares gained 3.9% to close at $281.21 on Friday, and added 0.1% in today’s pre-market trading session.

These analysts made changes to their price targets on HCA Healthcare following earnings announcement.

  • Citigroup raised the price target on HCA Healthcare from $293 to $324. Citigroup analyst Jason Cassorla maintained a Buy rating.
  • Oppenheimer increased the price target on HCA Healthcare from $270 to $310. Oppenheimer analyst Michael Wiederhorn maintained an Outperform rating
  • Credit Suisse increased the price target on HCA Healthcare from $282 to $311. Credit Suisse analyst A.J. Rice maintained the stock with an Outperform.


Read More: $59M Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPrice TargetPre-Market OutlookMarketsAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!